MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
XTL Biopharmaceuticals Ltd. ROE Ratio 2011-2026 | XTLB
Annual ROE Ratio XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -21.65 | -20.68 | 41.06 | -21.58 | -94.72 | -88.21 | -54.23 | -39.52 | -18.9 | -35.05 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.06 | -94.72 | -35.35 |
Quarterly ROE Ratio XTL Biopharmaceuticals Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -35.04 | -70.08 | -70.08 | -35.04 | -54.79 | -39.5 | -39.5 | -19.75 | -19.75 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -19.75 | -70.08 | -42.61 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.57 | -1.95 % | $ 1.39 B | Britain |
 |
Certara
CERT
|
-0.15 | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-69.87 | $ 18.1 | 1.17 % | $ 869 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Eton Pharmaceuticals
ETON
|
-6.05 | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
36.21 | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-98.61 | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-623.07 | $ 27.98 | 2.15 % | $ 364 M | USA |
 |
Galecto
GLTO
|
-118.61 | $ 29.63 | -1.39 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
24.88 | $ 27.76 | -6.37 % | $ 17.6 B | Danmark |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-97.53 | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
Hoth Therapeutics
HOTH
|
-119.04 | $ 1.01 | -0.98 % | $ 6.44 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
-7.84 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
-12.31 | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
1.79 | $ 9.95 | -0.4 % | $ 626 M | Germany |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Immunic
IMUX
|
1456.2 | $ 1.12 | 5.19 % | $ 174 M | USA |
 |
Agenus
AGEN
|
160.57 | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Immunovant
IMVT
|
-58.5 | $ 27.24 | -1.84 % | $ 4.13 B | USA |
 |
Inhibrx
INBX
|
-554.81 | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
-80.36 | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
-172.78 | $ 147.23 | 0.62 % | $ 29.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |